Supply Partnerships: Filament's Psilocybin Trial In Canada, PharmAla's MDMA Program In Australia

Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH

Clinical-stage natural psychedelic drug development company Filament Health Corp. FLHLF has inked a second supply deal with Canada-based Centre for Addiction and Mental Health (CAMH) concerning its botanical psilocybin drug candidate PEX010.

Specifically, CAMH will study the effects of psilocybin for the treatment of amnestic Mild Cognitive Impairment (aMCI) in a Health Canada-approved clinical trial.

Philip Gerretsen, who will co-lead the upcoming trial, explained that current treatments for aMCI are ineffective, and novel interventions must be researched “to help prevent progression to Alzheimer's Dementia (AD)," a situation for which there is no effective treatment currently. 

See Also: EXCLUSIVE - Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits

Accordingly, the current trial will examine if psilocybin can increase participants' synaptic density (aka synaptogenesis) and potentially counter neurodegeneration, as it has shown to do in prior animal studies.

"We're proud to continue building our relationship with CAMH, one of the world's most well-regarded mental health research institutions," Filament co-founder and CEO Benjamin Lightburn expressed. "Supporting Dr. Gerretsen and Dr. Graff's research by donating PEX010 advances Filament's mission to see safe, natural psychedelics into the hands of everyone who needs them, as soon as possible."

PharmAla Steps Foot In Australia With Proprietary MDMA

PharmAla Biotech Holdings Inc. has agreed to sell a shipment of its Good Manufacturing Practices (GMP)-compliant proprietary MDMA LaNeo to Australia-based drug development company Emyria Ltd. 

Amidst the country’s recent psychedelics legalization for the treatment of certain mental health conditions, PharmAla has submitted a national trademark application for LaNeo as well as the company’s brand name, which includes both EU-GMP MDMA and EU-GMP psilocybin products.

“Forward-looking companies are already moving to supply their clinical operations following the TGA’s regulatory change that will take effect on July 1. While this is a nascent industry, we are committed to responsibly supplying our customers as they develop operational capacity," PharmAla CEO Nick Kadysh said.

Kadysh recalls that the company has been active in Australia for a while, supplying LaNeo to three different clinical trials.

“We’re very pleased that, just 10 days after the change was announced, we’re in advanced discussions with a number of interested parties, and have already closed a new purchase order,” he concluded.

“We currently have a historic opportunity before us: to not only supply customers with high-quality EU-GMP API and drug products, but also to build one of the preeminent psychedelics operations in Australia — the country leading the world with regulations to support treatment," COO Shane Morris added.

Photo: Benzinga edit with photo by RF_studio on Pexels and anaterate on Pixabay.